First-in-human data presented at EuroPCR 2016 demonstrate that hemodynamic data from HeartFlow Inc. may help predict which coronary plaques have the potential to rupture.

Mitralign Inc. announced it has raised $39.8 million to date in a Series E equity round of financing.

Patients with a combination of left ventricular dysfunction and low aortic valve gradient have higher mortality rates and a greater risk of recurrent heart failure after transcatheter aortic valve replacement (TAVR).

Using optimal frequency domain imaging (OFDI) to guide percutaneous coronary intervention (PCI) with second-generation drug eluting stents (DES) achieves equivalent clinical and angiographic outcomes to intravascular ultrasound (IVUS)-guided PCI at 12 months.

Physician-researchers in the College of Medicine at the University of Cincinnati have developed a computerized decision support tool to assist physicians and patients with decisions about blood thinning treatment to prevent strokes in individuals with atrial fibrillation.

St. Jude Medical Inc. announced results from two cardiovascular clinical trials presented at EuroPCR 2016.

Bioabsorbable heart valves or blood vessels are designed to harness the body’s innate healing process, enabling the natural restoration of complex body parts as the synthetic graft is absorbed.